Dengue - Pipeline Review, H2 2012

Dengue – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Dengue - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Dengue, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dengue. Dengue - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Dengue.
- A review of the Dengue products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Dengue pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Dengue.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Dengue pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. SHOW LESS READ MORE >

2
List of Tables 7
List of Figures 8
Introduction 9
REPORT COVERAGE 9
Dengue Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Dengue 11
Dengue Therapeutics under Development by Companies 13
Dengue Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre-Clinical Stage Products 21
Comparative Analysis 21
Dengue Therapeutics – Products under Development by Companies 22
Dengue Therapeutics – Products under Investigation by Universities/Institutes 23
Companies Involved in Dengue Therapeutics Development 24
Vical Incorporated 24
GenVec, Inc. 25
Merck & Co., Inc. 26
Biotron Limited 27
Alfacell Corporation 28
AVI BioPharma Inc. 29
Medivir AB 30
NanoViricides, Inc. 31
SIGA Technologies, Inc. 32
MacroGenics, Inc. 33
Canopus BioPharma Incorporated 34
GenPhar, Inc. 35
Ikaria Inc. 36
Inviragen, Inc. 37
Dengue – Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 44
ranpirnase - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ST-148 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
IK-6003 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
HBV-001 D1 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
CB-5300 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
DengueCide - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
diethyltoluamide - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Dengue Vaccine - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
DENVax - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Drug For Dengue Virus - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
rDEN1delta30 Dengue Virus Vaccine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
rDEN3/4delta30 Vaccine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
rDEN4delta30-200,201 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
rDEN3-3'D4delta30 Dengue Vaccine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Dengue-1 Premembrane/Envelope DNA Vaccine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Dengue Type 2 Vaccine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
TetraVax-DV Vaccine-Admixture 1 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
TetraVax-DV Vaccine-Admixture 2 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
rDEN4delta30-109A - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Mult. mAbs/DARTs - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Virion Dengue - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Dengue Vaccine - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Dengue Anti-Virals - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Dengue Fever Vaccine - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
AVI-6006 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Dengue Vaccine - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Dengue Fever Vaccine - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
NS-3 Protease Inhibitor - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
squalamine lactate - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
rAmphinase 2 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
V-180 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Dengue Vaccine - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
ST-610 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Dengue Fever Vaccine - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Dengue Therapeutics – Drug Profile Updates 87
Dengue Therapeutics – Discontinued Products 91
Dengue Therapeutics - Dormant Products 92
Dengue – Product Development Milestones 93
Featured News & Press Releases 93
Jul 25, 2012: Sanofi Pasteur’s Dengue Vaccine Demonstrates Proof Of Efficacy 93
Mar 05, 2012: U.S. Navy Advances Dengue DNA Vaccine Using Vical's Vaxfectin Adjuvant 94
Dec 07, 2011: Inviragen Presents Safety And Immune Response Data From Phase I Study Of Two-Dose Dengue Vaccine, DENVax At ASTMH Meeting 94
Nov 28, 2011: Inviragen Initiates Phase II Clinical Study Of DENVax 95
Sep 19, 2011: Georgetown University Medical Center Researcher Proves Shark Compound To Be Potential Drug To Treat Human Viruses 96
Nov 04, 2010: Sanofi Pasteur’s Dengue Vaccine Enters First Phase III Clinical Study 98
Oct 25, 2010: Inviragen Initiates DENVax Phase I Clinical Testing In Colombia 98
Sep 14, 2010: Themis Bioscience And Institut Pasteur Form R&D Alliance To Fight Tropical Infectious Diseases Including Dengue 99
Jul 19, 2010: Tamir's Compounds Show Remarkable Results Against Dengue Virus 99
Jul 19, 2010: Tamir's Compounds Show Remarkable Results Against Dengue Virus 99
Appendix 100
Methodology 100
Coverage 100
Secondary Research 100
Primary Research 100
Expert Panel Validation 100
Contact Us 101
Disclaimer 101

List of Tables
Number of Products Under Development for Dengue, H2 2012 11
Products under Development for Dengue – Comparative Analysis, H2 2012 12
Number of Products under Development by Companies, H2 2012 14
Number of Products under Development by Companies, H2 2012 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2012 17
Comparative Analysis by Late Stage Development, H2 2012 18
Comparative Analysis by Mid Clinical Stage Development, H2 2012 19
Comparative Analysis by Early Clinical Stage Development, H2 2012 20
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 21
Products under Development by Companies, H2 2012 22
Products under Investigation by Universities/Institutes, H2 2012 23
Vical Incorporated, H2 2012 24
GenVec, Inc., H2 2012 25
Merck & Co., Inc., H2 2012 26
Biotron Limited, H2 2012 27
Alfacell Corporation, H2 2012 28
AVI BioPharma Inc., H2 2012 29
Medivir AB, H2 2012 30
NanoViricides, Inc., H2 2012 31
SIGA Technologies, Inc., H2 2012 32
MacroGenics, Inc., H2 2012 33
Canopus BioPharma Incorporated, H2 2012 34
GenPhar, Inc., H2 2012 35
Ikaria Inc., H2 2012 36
Inviragen, Inc., H2 2012 37
Assessment by Monotherapy Products, H2 2012 38
Assessment by Stage and Route of Administration, H2 2012 40
Assessment by Stage and Molecule Type, H2 2012 43
Dengue Therapeutics – Drug Profile Updates 87
Dengue Therapeutics – Discontinued Products 91
Dengue Therapeutics – Dormant Products 92

List of Figures
Number of Products under Development for Dengue, H2 2012 11
Products under Development for Dengue – Comparative Analysis, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 16
Late Stage Products, H2 2012 18
Mid Clinical Stage Products, H2 2012 19
Early Clinical Stage Products, H2 2012 20
Discovery and Pre-Clinical Stage Products, H2 2012 21
Assessment by Monotherapy Products, H2 2012 38
Assessment by Route of Administration, H2 2012 39
Assessment by Stage and Route of Administration, H2 2012 40
Assessment by Molecule Type, H2 2012 41
Assessment by Stage and Molecule Type, H2 2012 42